Tariff Ruling 'A Body Blow' for Trump
Original Report
Senior US officials say President Donald Trump's tariff defeat at the Supreme Court will not unravel trade deals negotiated with key US partners, as the administration moves to defend its assertive...
Senior US officials say President Donald Trump's tariff defeat at the Supreme Court will not unravel trade deals negotiated with key US partners, as the administration moves to defend its assertive trade policies. Agreements reached with China, the European Union, Japan and South Korea remain in place, US Trade Representative Jamieson Greer said on CBS's Face the Nation. However, Trump's pledge to reimpose tariffs at 15% on all nations could result in the UK facing the largest increase, up from its previous reciprocal tariff rate of 10%. Crawford Falconer, Former UK Chief Trade Negotiation Adviser and currently senior advisor to Bradshaw advisory joins Stephen Carroll and Caroline Hepker on Bloomberg Radio to discuss. (Source: Bloomberg)
Glass House Analysis
International economic policy has concrete impacts far beyond diplomatic circles. Tariffs show up in the price of goods at stores, supply chain disruptions affect whether products are on shelves, and trade tensions can mean job losses in export-dependent industries. The globalized economy means that decisions made abroad can affect workers and consumers domestically.
The implications extend beyond the immediate news cycle. Every economic development creates ripples that affect employment, prices, and opportunities in ways that may not be immediately visible but are deeply felt. By tracking these connections, we can better understand how the economy truly works—not as an abstract machine, but as a human system shaped by and shaping the lives of millions.
Enjoyed this analysis?
Get the Glass House Briefing every morning—market news that actually makes sense, delivered free to your inbox.
No spam. Unsubscribe anytime.
More Stories
Novo Nordisk pitted a new weight-loss drug against Eli Lilly’s — and lost
Novo Nordisk shares were under pressure on Monday as the struggling Danish pharmaceutical said a head-to-head study found a drug in development didn’t cut as much weight as an Eli Lilly product.